中国药房2016，Vol.27Issue(18)：2524-2527,4.DOI:10.6039/j.issn.1001-0408.2016.18.26
甘精胰岛素对比地特胰岛素治疗2型糖尿病的Meta分析
Insulin Glargine versus Insulin Detemir in the Treatment of Type 2 Diabetes:A Meta-analysis
摘要
Abstract
OBJECTIVE:To systematically review the efficacy and safety of insulin glargine versus insulin detemir in the treat-ment of type 2 diabetes,and provide evidence-based reference for clinical treatment. METHODS:Retrieved from PubMed,EM-Base,Cochrane Library,CBM,CJFD,VIP and Wanfang database,randomized controlled trials (RCT) about the clinical efficacy and safety of insulin glargine versus insulin detemir in the treatment of type 2 diabetes were collected. Meta-analysis was performed by using Rev Man 5.2 software after data extraction and quality evaluation by Cochrane 5.1.0. RESULTS:A total of 18 RCTs,in-volving 3 638 patients were included. Results of Meta-analysis showed there was no significant difference in reducing glycosylated hemoglobin[MD=0.08,95%CI (-0.01,0.17),P=0.09];fasting blood glucose level in insulin glargine group was significantly lower thaninsulin detemir,the difference was statistically significant [MD=0.15,95%CI(0.03,0.27),P=0.02]. And there was no significant difference in the incidence of hypoglycemia [OR=0.97,95%CI(0.91,1.03),P=0.25];the degree of body mass gain ininsulin detemir was significantly lower than insulin glargine group [MD=-0.95,95%CI(-1.06,-0.85),P=0.003],but the in-cidence of injection site reactions was significantly higher than insulin glargine group [OR=2.28,95%CI(1.16,4.50),P=0.02],the differences were statistically significant. CONCLUSIONS:The insulin glargine has better efficacy,than insulin detemir with lower incidence of injection site reactions but higher degree of body mass gain than insulin detemir in the treatment of type 2 diabetes.关键词
甘精胰岛素/地特胰岛素/2型糖尿病/Meta分析/疗效/安全性Key words
Insulin glargine/Insulin detemir/Type 2 diabetes/Meta-analysis/Efficacy/Safety分类
医药卫生引用本文复制引用
范峥,郭桂明,李文喆,薛颖,王宏蕾,李璐暘,肖薇..甘精胰岛素对比地特胰岛素治疗2型糖尿病的Meta分析[J].中国药房,2016,27(18):2524-2527,4.基金项目
国家科技支撑计划子课题 （）
